News Archive

October 19, 2026

After FDA rejection, Disc Medicine’s ‘sun allergy’ drug hits home run in Phase 3

  • Portfolio Company News
Read more
October 8, 2026

Matchpoint nets $150M series B to take covalent med into clinic

  • Portfolio Company News
Read more
August 17, 2026

Make US INDs Great Again

  • From the Trenches
Read more
August 6, 2026

FDA approves Replimune melanoma drug previously rejected twice

  • Portfolio Company News
Read more
July 29, 2026

Less than year after launch, Caldera lines up $278M financing and Nasdaq debut

  • Portfolio Company News
Read more